在复发性耐火多发性骨髓瘤中对达拉图巴基疗法的耐药性的基因组和免疫决定因素

Bachisio Ziccheddu1, Claudia Giannotta2, Mattia D'Agostino3

  • 1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.

Blood cancer journal
|July 19, 2024
PubMed
概括

基因组复杂性和免疫变化导致复发性/耐药性多发性骨髓瘤 (RRMM) 中对达拉图巴基疗法的耐药性. 了解这些因素可以改善RRMM患者的治疗策略.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K